Teva has failed in its appeal against fines totaling €60.5m ($63.8m) imposed on it and Cephalon – itself now part of Teva – in connection to an unlawful “pay-for-delay” arrangement covering European generic competition to Provigil (modafinil).
The General Court of the Court of Justice of the EU has upheld a European Commission decision from 2020...





